William Blair
William Blair Initiates Coverage of Bio-Techne With Outperform Rating
The investment bank emphasized Bio-Techne's position in multiple high-growth and attractive end markets, including cell and gene therapy, spatial biology, and liquid biopsy.
William Blair Initiates Coverage of MDxHealth With Outperform Rating
A letter to investors noted the company's dedicated focus on prostate cancer diagnostics, which de-risks the firm's growth outlook and path to profitability.
William Blair Downgrades Lucira Health to Market Perform
As a result of the downgrade, the bank also significantly reduced revenue and volume estimates for 2021 and 2022.
Exagen Prices $60.1M Public Offering of Stock
The company said it plans to use the proceeds to develop multiomics capabilities, including building out its clinical laboratory.
Roche to Acquire GenMark Diagnostics for $1.8B
Under the acquisition agreement, expected to close in Q2, Roche will acquire all outstanding shares of GenMark's common stock for $24.05 per share.
Oct 14, 2019
William Blair, Cowen Initiate Coverage of Exagen
Jun 26, 2019
Vermillion Eyes $17M in Public Offering of Stock
Jul 26, 2018